Drug General Information
Drug ID	D0I2YV
Former ID	DIB013351
Drug Name	BIBB-515
Drug Type	Small molecular drug
Indication	Arteriosclerosis [ICD9: 440; ICD10:I70]		Terminated	[534359]
Company	Dr Karl Thomae GmbH
Structure		Download 2D MOL 3D MOL
Formula	C22H21ClN2O2
Canonical SMILES	C(=O)(N1CCC(=Cc2ccc(C3=NCCO3)cc2)CC1)c1ccc(cc1)Cl
CAS Number	CAS 156635-05-1
PubChem Compound ID	501398
Target and Pathway
Target(s)	Lanosterol synthase	Target Info	Modulator	[526088], [534359]
BioCyc Pathway	Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)
	Cholesterol biosynthesis III (via desmosterol)
	Cholesterol biosynthesis I
	Superpathway of cholesterol biosynthesis
	Lanosterol biosynthesis
KEGG Pathway	Steroid biosynthesis
	Metabolic pathways
	Biosynthesis of antibiotics
PANTHER Pathway	Cholesterol biosynthesis
PathWhiz Pathway	Steroid Biosynthesis
Reactome	Cholesterol biosynthesis
	Activation of gene expression by SREBF (SREBP)
WikiPathways	Activation of Gene Expression by SREBP (SREBF)
	SREBP signalling
	Cholesterol Biosynthesis
	Cholesterol biosynthesis
References
Ref 534359	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
Ref 526088	Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
Ref 534359	Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.